Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chimerix (CMRX)
NASDAQ:CMRX
Holding CMRX?
Track your performance easily
CMRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.75 - $3.39
Previous Close$2.99
Volume2.53M
Average Volume (3M)3.77M
Market Cap
$256.32M
Enterprise Value$144.38M
Total Cash (Recent Filing)$112.58M
Total Debt (Recent Filing)$644.00K
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Mar 04, 2025EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding89,936,053
10 Day Avg. Volume22,857,366
30 Day Avg. Volume3,767,525
Standard Deviation0.20
R-Squared0.07
Alpha-0.00955
Financial Highlights & Ratios
Price to Book (P/B)1.98
Price to Sales (P/S)1612.06
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue908.03
Enterprise Value/Gross Profit445.61
Enterprise Value/Ebitda-1.58
Forecast
1Y Price Target
$8.00Price Target Upside167.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Chimerix News
PremiumMarket News
3 Penny Stocks to Watch Now, 12/12/24Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsImpressive Phase 2 data for dordaviprone reported an overall response rate of 28.0%, suggesting promising prospects for its approval.
Drug Approval And Market PotentialDordaviprone was previously granted FDA Fast Track Designation and Rare Pediatric Disease Designation, indicating its potential significance in treating H3 K27M-mutant glioma.
Market Demand And Unmet NeedThere is a significant unmet need as H3 K27M diffuse glioma patients currently have no proven effective therapies.
Bears Say
Effectiveness ConcernsMedian duration of response decreased to 10.4 months, indicating a shorter period of effectiveness.
Operational RisksRisks include commercial, regulatory, clinical, manufacturing, financial, liability, and intellectual challenges.
Regulatory ChallengesProvisional approval in Australia has been pushed back to focus on the U.S. NDA filing.
---
Ownership Overview
5.69% Insiders
7.26% Mutual Funds
23.81% Other Institutional Investors
58.56% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CMRX FAQ
What was Chimerix’s price range in the past 12 months?
Chimerix lowest stock price was $0.75 and its highest was $3.39 in the past 12 months.
What is Chimerix’s market cap?
Currently, no data Available
When is Chimerix’s upcoming earnings report date?
Chimerix’s upcoming earnings report date is Mar 04, 2025 which is in 72 days.
How were Chimerix’s earnings last quarter?
Chimerix released its earnings results on Nov 07, 2024. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.236 by -$0.024.
Is Chimerix overvalued?
According to Wall Street analysts Chimerix’s price is currently Undervalued.
Does Chimerix pay dividends?
Chimerix does not currently pay dividends.
What is Chimerix’s EPS estimate?
Chimerix’s EPS estimate is -$0.25.
How many shares outstanding does Chimerix have?
Chimerix has 89,936,050 shares outstanding.
What happened to Chimerix’s price movement after its last earnings report?
Chimerix reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.236. Following the earnings report the stock price went down -6.931%.
Which hedge fund is a major shareholder of Chimerix?
Among the largest hedge funds holding Chimerix’s share is RA Capital Management. It holds Chimerix’s shares valued at 8M.
---
Chimerix Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (167.56% Upside)
$8.00 (167.56% Upside)
Blogger Sentiment
Bullish
CMRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.7%
Last 30 Days ▲ 9.2%
Last 30 Days ▲ 9.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
218.08%
12-Months-Change
Fundamentals
Return on Equity
-48.59%
Trailing 12-Months
Asset Growth
-29.57%
Trailing 12-Months
Company Description
Chimerix
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
---
CMRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant progress in clinical studies and a strong financial position, despite the increased research expenses and net loss. The positive developments in the pipeline and financial management outweigh the challenges.Read More>---
CMRX Stock 12 Month Forecast
Average Price Target
$8.00
▲(167.56% Upside)
Technical Analysis
Aurinia Pharmaceuticals
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Mersana Therapeutics
―
Best Analysts Covering CMRX
1 Year
1 Year Success Rate
11/25 ratings generated profit
1 Year Average Return
+24.14%
reiterated a buy rating 12 days ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 44.00% of your transactions generating a profit, with an average return of +24.14% per trade.
---